In October 2020, during the height of the COVID-19 pandemic, Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for their development of a method for genome editing. Their work on CRISPR-Cas9 represented a major advance in humanity's ability not merely to read genetic code, but to edit it with remarkable precision. It was also historic as the first time an all-female team had shared a Nobel Prize. That transition, from sequencing and understanding biological systems to selectively modifying them, provides a particularly relevant lens through which to view the ETF industry's next phase of development.
The ETF industry is approaching an analogous point of development.
For its first three decades, the ETF market largely resembled classical observational biology. Broad products tracking the S&P 500, global equities, investment-grade bonds, or other market benchmarks gave investors efficient, low-cost access to whole market organisms. For advisers, they became indispensable building blocks: liquid, transparent, scalable, and easy to implement.
But broad exposure has limits. A cap-weighted equity index brings with it every feature of its composition: concentration in large companies, cyclical sensitivity, valuation risk, duration exposure, and the full force of market drawdowns. It is an efficient portfolio component, but not necessarily a precisely calibrated client outcome.
The next phase of ETF development is therefore less about creating another broad market tracker and more about financial genomics: identifying the underlying characteristics of a portfolio, isolating specific risk-and-return exposures, and recombining them to create more intentional outcomes.
For US Registered Investment Advisers and UK Independent Financial Advisers, this shift has important implications. The ETF has evolved from a simple index container into a flexible portfolio-engineering tool.
The ETF's Molecular Architecture: Creation and Redemption as Enzymatic Machinery
The ETF's ability to support this evolution rests on an infrastructure that is often invisible to end investors: the primary-market creation and redemption process.
In biology, enzymes facilitate molecular activity. They allow complex transformations to take place efficiently, selectively, and repeatedly. The ETF ecosystem has an equivalent mechanism in the relationship among the ETF issuer, portfolio manager, and authorised participants.
When demand for an ETF rises, an authorised participant can generally deliver a basket of underlying securities, or where permitted, a customised basket, to the fund in exchange for newly created ETF shares. When ETF shares are redeemed, the process works in reverse: the authorised participant returns ETF shares and receives a basket of securities.
This machinery helps keep ETF prices close to net asset value, but its importance goes further. It enables the ETF portfolio to evolve without requiring every investor transaction to trigger fund-level selling. In the US, this in-kind mechanism can be especially valuable in taxable accounts because it may help reduce the need for taxable capital-gain distributions relative to conventional mutual-fund structures.
In the US the SEC's Rule 6c-11 provided a more standardised regulatory framework for many ETFs, including flexibility around custom baskets subject to appropriate policies and controls. That matters because it allows portfolio managers to treat holdings less like permanent fixtures and more like components that can be adjusted as a portfolio's desired exposures change.
For advisers, the practical message is simple: ETF innovation is not solely about product marketing or new index labels. It is supported by a distribution and portfolio management structure capable of making increasingly sophisticated strategies operationally scalable.
Defined-Outcome ETFs: Financial CRISPR
The clearest evidence of ETF product development moving toward precision engineering is the growth of defined-outcome, buffer, and other structured-payoff ETFs.
These strategies use options, often FLEX options, to reshape the return profile of an equity-market exposure over a defined outcome period. In broad terms, an investor may exchange a portion of potential upside for a specified degree of downside protection, subject to the product's terms, caps, buffers, fees, and timing.
The comparison with CRISPR is useful. CRISPR did not replace biology; it made it possible to alter targeted parts of a biological system. Defined-outcome ETFs do not eliminate equity market risk, nor do they guarantee superior returns. They allow advisers to modify specific elements of market exposure: a portion of downside, the range of upside participation, or the pattern of returns across a stated period.
For advisers working with clients approaching retirement, drawing income, or managing a reduced capacity for loss, that can be highly relevant. A conventional equity allocation offers open-ended upside but also full participation in market declines. A buffered strategy may offer a more explicitly designed trade-off: a stated level of downside protection over a defined period; a cap or limit on upside participation; continued exposure to an equity-market reference asset; and daily exchange trading, although liquidity and pricing should always be assessed in the context of the underlying holdings and options structure.
The defined-outcome ETF market has become increasingly concentrated around a small group of specialist and large-platform providers. First Trust / FT Vest and Innovator ETFs are the central names in the category, together representing approximately 86% of the roughly $78 billion defined outcome market at the end of 2025.
Innovator is closely associated with pioneering the buffer ETF category, while First Trust / FT Vest has become a leading scaled provider. Around them, an increasingly broad ecosystem has emerged, including Allianz Investment Management (AllianzIM), AllianceBernstein, Pacer, iShares / BlackRock, Calamos, PGIM and Aptus Capital Advisors.
These providers differ in implementation, underlying exposures, buffer levels, outcome periods, caps, fees, and portfolio applications. That diversity is important. Defined outcome is not a single strategy; it is a family of payoff designs that require careful due diligence.
For RIAs, the attraction is often the ability to communicate a more explicit risk budget within a client portfolio. For UK IFAs, the equivalent attraction may be the ability to evidence a clearer relationship between a client's stated risk tolerance, capacity for loss, and the design of the investment solution, particularly in an environment shaped by the FCA's Consumer Duty expectations around demonstrable client value and suitability.
Structured-outcome ETFs have therefore become a North Star for the ETF industry. They demonstrate that the wrapper can support not only broad-market exposure but also a more programmable payoff structure.
Active ETFs: Sequencing for Alpha and Factor Precision
The same precision trend is visible in the rapid expansion of active ETFs. The old active versus passive debate is becoming less useful. The more relevant question is how an adviser combines broad, low-cost market exposure with targeted strategies designed to express a particular investment view, income objective, risk preference, or factor profile.
Active ETFs represent the sequencing stage of financial genomics. Instead of accepting an index as a fixed organism, the manager evaluates the portfolio's constituent base: profitability, cash-flow quality, valuation, capital allocation, balance-sheet resilience, momentum, duration, credit quality, yield, and other drivers of returns.
The objective is not simply to own fewer stocks or to make discretionary forecasts. In many cases, it is to assemble a portfolio with a more deliberate exposure to chosen characteristics while reducing unintended risks. For advisers, however, the point is not to assume that active management automatically produces better outcomes. Manager selection, process discipline, fees, capacity, portfolio overlap, liquidity, tax treatment, and the role of the strategy within the overall allocation remain critical.
The more important development is structural: advisers can increasingly access active security selection, systematic factor implementation, equity income, active fixed income, and differentiated portfolio construction within the same liquid ETF framework that once primarily delivered benchmark exposure.
From Generic Allocation to Designer Portfolios
For US RIAs and UK IFAs, financial genomics changes the conversation from product selection to portfolio design. A broad index ETF may remain the essential core holding cheap, diversified and transparent investments, and difficult to improve upon for many objectives. But increasingly, it can be combined with more specialised genetic components. This is not an argument for complexity for its own sake. A more complicated portfolio is not inherently a better portfolio. The purpose of greater precision is to make the connection between the client's needs and the portfolio's design more explicit.
That is particularly relevant in the current regulatory environment. US RIAs must be able to evidence that recommendations are consistent with their fiduciary responsibilities. UK IFAs face an increased focus on client outcomes, suitability, fair value, and the practical application of Consumer Duty. In both markets, a portfolio that can be explained in terms of clearly defined roles, risks, and expected trade-offs is easier to defend than one assembled solely from legacy product categories.
Like genome science, ETF innovation is moving from observation to sequencing, and from sequencing to engineering. The advisers best positioned for this next phase will not necessarily be those with the most complex portfolios. They will be those who understand which exposures are genuinely needed, which risks can be more deliberately managed, and how to assemble those components into resilient, comprehensible client outcomes.
Irene Bauer